Drug intelligence / Profile preview

p-321

Development stage: Phase 1
Lead developer: Parion Sciences
Modality: Small Molecules
Administration: Ophthalmic, Topical

Overview

P-321 is a potent inhibitor of the epithelial sodium channels (ENaC) on the ocular surface. It is designed to restore the tear film in patients with dry eye disease. The drug is formulated as an ophthalmic solution for topical application.

Targets

ENaC

Beyond the preview

Go deeper on p-321.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on p-321.

Explore the full profile